IDEXX Laboratories Announces Second Quarter Results

This webcast and the statements to be made in the accompanying earnings conference call contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking statements are included above under "2026 Growth and Financial Performance Outlook" and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures, including anticipated investments in global commercial capabilities and innovation; projected tax, tax rate and EPS benefits from share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense; trends and other factors impacting the pet healthcare industry, including pet population demographics and U.S. clinical visits, and their anticipated effects on the Company; IDEXX inVue Dx™ analyzer placements; IDEXX Cancer Dx™ testing panel expansion; rollout of Fine Needle Aspiration to the IDEXX inVue Dx analyzer; and future commercial expansions. These statements are intended to provide management's expectations or forecasts of future events as of the date of this webcast; are based on management's estimates, projections, beliefs, and assumptions as of the date of this webcast; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the adverse impact, and the duration, of macroeconomic events, conditions, and uncertainties, such as geopolitical instability (including wars, terrorist attacks, and armed conflicts), general economic uncertainty, changes in U.S. and other countries’ tariff and trade policies, severe weather and other natural conditions, and supply chain challenges on our business, results of operations, liquidity, financial condition, and stock price, as well as the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in the corresponding sections of the Company's Quarterly Report on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, as well as those described from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

• Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.

• Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics utilization.

• IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter.

• Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as reported and 110 basis points on a comparable basis.

• Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5 million at midpoint, reflecting benefit of CAG Diagnostics recurring revenue performance, and net of $15 million headwind from updated foreign exchange estimates.

• Raises midpoint for 2026 reported revenue growth outlook to 9.7%, reflecting a range of 9.1% - 10.3%, and CAG Diagnostics recurring revenue reported growth of 10.1% - 11.3%, with projected 2026 organic revenue growth of 8.5% - 9.7% and CAG Diagnostics recurring revenue organic growth of 9.5% - 10.7%.

• Increases 2026 EPS outlook to $14.69 - $14.94, reflecting an increase of $0.14 compared to prior guidance midpoint, supported by a raised revenue outlook at midpoint while advancing incremental investments aligned with commercial and innovation priorities.

WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results.

The Company reports revenues of $1,217 million for the second quarter of 2026, an increase of 10% as reported and 9% organic, driven by Companion Animal Group ("CAG") growth of 9% as reported and organic, Water revenue growth of 15% as reported and 13% organic, and LPD revenue growth of 11% as reported and 9% organic.

Second quarter earnings per diluted share (“EPS”) were $4.27, an increase of 18% as reported and 15% on a comparable basis. Second quarter EPS included $0.14 per share in tax benefits from share-based compensation and $0.06 per share benefit from year-over-year currency changes.

“Our second quarter results reflect the strength of our Technology for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supporting deeper customer adoption and higher diagnostic utilization,” said Mike Erickson, President and Chief Executive Officer. “This is the kind of durable, compounding growth we're building for the long term, helping veterinarians see more and do more for their patients while creating lasting value for our shareholders.”

CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic, including 14% reported and 12% organic gains in International regions, and 10% reported and organic growth in the U.S., outpacing sector growth levels.

Additional U.S. companion animal practice key metrics are available in the Q2 2026 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.

Exceptional commercial execution - including strong volume gains, net customer expansion, benefits from IDEXX innovation, and growth of the premium instrument installed base - drove double-digit CAG Diagnostics recurring revenue growth.

• IDEXX VetLab™ consumables generated 15% reported and 14% organic revenue growth, supported by testing utilization gains, including benefits from recent product launches and net new customer growth with 11% expansion of the IDEXX global premium instrument installed base and net price gains.

• Reference laboratory diagnostic and consulting services generated 11% reported and 10% organic revenue growth, driven by higher testing volumes and net new customer gains.

• Rapid assay products revenues increased 1% as reported and on an organic basis, driven by net price benefits and an easing of the volume impacts from adoption of the Catalyst™ Pancreatic Lipase Test, which has shifted some testing across modalities.

CAG Diagnostics capital instrument revenues decreased 19% as reported and 20% on an organic basis, lapping the Q2 2025 broad availability of IDEXX inVue Dx, with current-year period revenue benefiting from over 1,600 IDEXX inVue Dx placements.

Veterinary software, services and diagnostic imaging systems revenues grew 12% on a reported and organic basis for the quarter, with benefits from cloud-native software growth and installed base expansion. Diagnostic imaging systems delivered another record quarter of installations, led by ImageVue™ DR50 Plus.

Water revenues grew 15% as reported and 13% organic for the quarter, reflecting solid organic growth in the U.S. and Europe.

LPD revenues increased 11% as reported and 9% organic for the quarter, led by strong growth in the Americas.

Gross profit increased 12% as reported and 11% on a comparable basis. Gross margin of 64.0% increased 140 basis points as reported and 120 basis points on a comparable basis, supported by strong recurring revenue volume gains, operational productivity initiatives, and net price realization.

Operating margin was 35.0% for the quarter, higher than the prior year period by 140 basis points as reported and by 110 basis points on a comparable basis. Operating margin results reflect a 10% operating expense increase as reported and 9% growth on a comparable basis. Operating expense growth supported expansion of commercial capabilities, advancement of the Company's innovation agenda, and enabling information technology investments.

The Company is updating its full year revenue growth guidance range to $4,700 million - $4,745 million, or reported growth of 9.1% - 10.3%, an increase of $5 million at midpoint, net of a $15 million reduction to projected revenues from a stronger U.S. dollar. The Company is increasing its outlook for organic revenue growth to 8.5% - 9.7%, an increase of 0.4% at midpoint, reflecting operational performance.

The Company increased its full year reported operating margin outlook to 32.3% - 32.5%, bringing the projected full year operating profit margin expansion to 70 - 90 basis points as reported and on a comparable basis. This outlook benefits from strong second quarter operating performance, while advancing strategic investment priorities.

The Company updated its EPS outlook range to $14.69 - $14.94, reflecting increased reported growth of 12% - 14% and 13% - 15% comparable growth. At midpoint this reflects benefits of $0.14 per share from operational performance; $0.05 from higher share-based compensation benefits and a $0.05 headwind from updated estimates for foreign exchange impacts.

The following table provides the Company's updated outlook for annual key financial metrics in 2026 with a comparison to the prior outlook:

Amounts in millions except per share data and percentages

2026 Growth and Financial Performance Outlook | | | | | | | |

| | Updated | | Prior

Revenue | | $4,700 | - | $4,745 | | $4,675 | - | $4,760

Reported growth | | 9.1% | - | 10.3% | | 8.6% | - | 10.6%

Organic growth | | 8.5% | - | 9.7% | | 7.7% | - | 9.7%

CAG Diagnostics Recurring Revenue Growth | | | | | | | |

Reported growth | | 10.1% | - | 11.3% | | 9.6% | - | 11.6%

Organic growth | | 9.5% | - | 10.7% | | 8.7% | - | 10.7%

Operating Margin | | 32.3% | - | 32.5% | | 32.1% | - | 32.5%

Operating margin expansion | | 70 bps | - | 90 bps | | 50 bps | - | 90 bps

Comparable margin expansion | | 70 bps | - | 90 bps | | 50 bps | - | 90 bps

EPS | | $14.69 | - | $14.94 | | $14.45 | - | $14.90

Reported growth | | 12% | - | 14% | | 11% | - | 14%

Comparable growth | | 13% | - | 15% | | 11% | - | 15%

Other Key Metrics | | | | | | | |

Net interest expense | | ~ $35 | | ~ $34

Share-based compensation tax benefit | | ~ $19 | | ~ $15

Share-based compensation tax rate benefit | | ~ 1.3% | | ~ 1.0%

Effective tax rate | | ~ 21.1% | | ~ 21.4%

Share-based compensation EPS impact | | ~ $0.24 | | ~ $0.19

Reduction in average shares outstanding | | 1.5% | - | 2% | | 1% | - | 2%

Operating Cash Flow (% of Net Income) | | 110% | - | 120% | | 105% | - | 115%

Free Cash Flow (% of Net Income) | | 90% | - | 100% | | 85% | - | 95%

Capital Expenditures | | ~ $180 | | ~ $180

Net interest expense

~ $35

~ $34

Share-based compensation tax benefit

~ $19

~ $15

Share-based compensation tax rate benefit

~ 1.3%

~ 1.0%

Effective tax rate

~ 21.1%

~ 21.4%

Share-based compensation EPS impact

~ $0.24

~ $0.19

Reduction in average shares outstanding

1.5%

-

2%

1%

-

2%

Capital Expenditures

~ $180

~ $180

The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2026.

Estimated Foreign Currency Exchange Rate Impacts | | 2026

Revenue growth rate impact | | ~0.6%

CAG Diagnostics recurring revenue growth rate impact | | ~0.6%

Operating margin growth impact | | ~ 30 bps

EPS impact | | ~ $0.22

EPS growth impact | | ~ 2%

Go-Forward Foreign Currency Exchange Rate Assumptions | | 2026

In U.S. dollars | | | |

euro | | $1.14

British pound | | $1.32

Canadian dollar | | $0.70

Australian dollar | | $0.69

Relative to the U.S. dollar | | | |

Japanese yen | | ¥162

Chinese renminbi | | ¥6.80

Brazilian real | | R$5.20

Revenue growth rate impact

~0.6%

CAG Diagnostics recurring revenue growth rate impact

~0.6%

Operating margin growth impact

~ 30 bps

EPS impact

~ $0.22

EPS growth impact

~ 2%

In U.S. dollars

euro

$1.14

British pound

$1.32

Canadian dollar

$0.70

Australian dollar

$0.69

Relative to the U.S. dollar

Japanese yen

¥162

Chinese renminbi

¥6.80

Brazilian real

R$5.20

IDEXX Laboratories, Inc. will host a conference call today at 8:30 a.m. (ET) to discuss its second quarter 2026 results and management’s outlook. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. (ET) via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 922025.

IDEXX Laboratories, Inc. will host its 2026 Investor Day on Thursday, August 13, 2026 from 8:00 am to approximately 12:00 pm (ET). A live webcast and accompanying slide presentations will be available at www.idexx.com/investors. An archived webcast replay of the event will be available approximately one hour following the event at www.idexx.com/investors. For additional information, contact investorrelations@idexx.com.

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.

This earnings release and the statements to be made in the accompanying earnings conference call contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking statements are included above under "2026 Growth and Financial Performance Outlook" and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures, including anticipated investments in global commercial capabilities and innovation; projected tax, tax rate and EPS benefits from share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense; trends and other factors impacting the pet healthcare industry, including pet population demographics and U.S. clinical visits, and their anticipated effects on the Company; IDEXX inVue Dx analyzer placements; IDEXX Cancer Dx testing panel expansion; rollout of Fine Needle Aspiration to the IDEXX inVue Dx analyzer; and future commercial expansions. These statements are intended to provide management's expectations or forecasts of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs, and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the adverse impact, and the duration, of macroeconomic events, conditions, and uncertainties, such as geopolitical instability (including wars, terrorist attacks, and armed conflicts), general economic uncertainty, changes in U.S. and other countries’ tariff and trade policies, severe weather and other natural conditions, and supply chain challenges on our business, results of operations, liquidity, financial condition, and stock price, as well as the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in the corresponding sections of the Company's Quarterly Report on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, as well as those described from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company’s consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors’ evaluation of the Company’s business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company’s business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimate the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted second quarter 2026 results as follows: increased gross profit growth by 1.1%, increased gross margin expansion 20 basis points, increased operating expense growth by 0.5%, increased operating profit growth by 1.6%, increased operating profit margin growth by 30 basis points, and increased EPS growth by 1.7%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three and six months ended June 30, 2026 and refer to the 2026 Growth and Financial Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2026 projections and estimates.

Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that represents the percentage change in revenue, as compared to the same period for the prior year, net of the effect of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three and six months ended June 30, 2026. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Please refer to the 2026 Growth and Financial Performance Outlook section of this earnings release for estimated full year 2026 organic revenue growth for the Company and CAG Diagnostics recurring revenue growth. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is expected to have an immaterial impact on projected full year 2026 revenue growth and no impact on CAG Diagnostics recurring revenue growth.

We exclude from organic revenue growth the effect of changes in foreign currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility, and can obscure underlying business trends. We calculate the impact on revenue resulting from changes in foreign currency exchange rates by applying the difference between the weighted average exchange rates during the current year period and the comparable prior year period to foreign currency denominated revenues for the prior year period.

We also exclude from organic revenue growth the effect of certain business acquisitions and divestitures because the nature, size, and number of these transactions can vary dramatically from period to period, and because they either require or generate cash as an inherent consequence of the transaction, and therefore can also obscure underlying business and operating trends. We consider acquisitions to be a business when all three elements of inputs, processes, and outputs are present, consistent with ASU 2017-01, “Business Combinations: (Topic 805) Clarifying the Definition of a Business.” We do not consider acquired assets to be a business if substantially all the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. A typical acquisition that we do not consider a business is a customer relationship asset acquisition, which does not have all elements necessary to operate a business, such as employees or infrastructure. Revenue from these customers acquired is included in organic revenue growth because we believe the efforts required to convert and retain these acquired customers are similar in nature to our efforts to obtain and retain our existing customer base.

Comparable growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.

The reconciliation of these non-GAAP financial measures is as follows:

| | Three Months Ended | | Year-over-Year | | Six Months Ended | | Year-over-Year

| | June 30, | | June 30, | | Change | | June 30, | | June 30, | | Change

Dollar amounts in thousands | | 2026 | | 2025 | | | | 2026 | | 2025 | |

Gross profit and growth (as reported) | | $ | 779,087 | | | $ | 694,732 | | | 12 | % | | $ | 1,501,826 | | | $ | 1,318,111 | | | 14 | %

Gross margin and margin gain | | | 64.0 | % | | | 62.6 | % | | 140 bps | | | 63.7 | % | | | 62.5 | % | | 120 bps

Less: comparability adjustments | | | | | | | | | | | |

Change from currency | | | 7,511 | | | | — | | | | | | 27,982 | | | | — | | |

Comparable gross profit and growth | | $ | 771,576 | | | $ | 694,732 | | | 11 | % | | $ | 1,473,844 | | | $ | 1,318,111 | | | 12 | %

Comparable gross margin and margin gain | | | 63.9 | % | | | 62.6 | % | | 120 bps | | | 63.6 | % | | | 62.5 | % | | 110 bps

Operating expenses and growth (as reported) | | $ | 353,521 | | | $ | 321,686 | | | 10 | % | | $ | 713,674 | | | $ | 628,531 | | | 14 | %

Less: comparability adjustments | | | | | | | | | | | |

Change from currency | | | 1,458 | | | | — | | | | | | 7,728 | | | | — | | |

Loss on equity investment | | | — | | | | — | | | | | | 5,000 | | | | — | | |

Now-concluded litigation matter | | | — | | | | — | | | | | | | — | | | | (8,600) | | | |

Comparable operating expense and growth | | $ | 352,063 | | | $ | 321,686 | | | 9 | % | | $ | 700,946 | | | $ | 637,131 | | | 10 | %

Operating profit and growth (as reported) | | $ | 425,566 | | | $ | 373,046 | | | 14 | % | | $ | 788,152 | | | $ | 689,580 | | | 14 | %

Operating margin and margin gain | | | 35.0 | % | | | 33.6 | % | | 140 bps | | | 33.4 | % | | | 32.7 | % | | 70 bps

Less: comparability adjustments | | | | | | | | | | | |

Change from currency | | | 6,053 | | | | — | | | | | | 20,254 | | | | — | | |

Loss on equity investment | | | — | | | | — | | | | | | (5,000 | ) | | | — | | |

Now-concluded litigation matter | | | — | | | | — | | | | | | — | | | | 8,600 | | |

Comparable operating profit and growth | | $ | 419,513 | | | $ | 373,046 | | | 12 | % | | $ | 772,898 | | | $ | 680,980 | | | 13 | %

Comparable operating margin and margin gain | | | 34.7 | % | | | 33.6 | % | | 110 bps | | | 33.3 | % | | | 32.3 | % | | 100 bps

Amounts presented may not recalculate due to rounding. | | | | | |

Dollar amounts in thousands

64.0

%

62.6

%

63.7

%

62.5

%

Less: comparability adjustments

Change from currency

7,511

—

27,982

—

63.9

%

62.6

%

63.6

%

62.5

%

Less: comparability adjustments

Change from currency

1,458

—

7,728

—

Loss on equity investment

—

—

5,000

—

—

—

—

(8,600)

35.0

%

33.6

%

33.4

%

32.7

%

Less: comparability adjustments

Change from currency

6,053

—

20,254

—

Loss on equity investment

—

—

(5,000

)

—

Now-concluded litigation matter

—

—

—

8,600

Amounts presented may not recalculate due to rounding.

Projected 2026 comparable operating margin expansion outlined in the 2026 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) full year 2026 reported operating margin adjusted for a $5 million unfavorable impact of loss on an equity investment; (ii) adjustment to projected 2026 operating margin for a positive impact from year-over-year foreign currency exchange rate changes at noted exchange rates; and (iii) adjustment to 2025 operating margin for the positive impact of the approximately $9 million discrete litigation expense accrual adjustment in the second quarter of 2025.

These impacts described above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2026) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.

Comparable EPS growth - Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, "Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting," and non-recurring or unusual items (if any). Management believes comparable EPS growth is a more useful way to measure the Company’s business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.

The reconciliation of this non-GAAP financial measure is as follows:

| | Three Months Ended | | Year-over-Year | | Six Months Ended | | Year-over-Year

| | June 30, | | June 30, | | Growth | | June 30, | | June 30, | | Growth

| | 2026 | | 2025 | | | | 2026 | | 2025 | |

Earnings per share (diluted) and growth | | $ | 4.27 | | $ | 3.63 | | 18 | % | | $ | 7.74 | | | $ | 6.59 | | 17 | %

Less: comparability adjustments | | | | | | | | | | | |

Share-based compensation activity | | | 0.14 | | | 0.10 | | | | | 0.23 | | | | 0.11 | |

Loss on equity investment | | | — | | | — | | | | | (0.05 | ) | | | — | |

Now-concluded litigation matter | | | — | | | — | | | | | — | | | | 0.08 | |

Change from currency | | | 0.06 | | | — | | | | | 0.20 | | | | — | |

Comparable EPS and growth | | $ | 4.07 | | $ | 3.53 | | 15 | % | | $ | 7.36 | | | $ | 6.40 | | 15 | %

Amounts presented may not recalculate due to rounding. | | | | | |

$

4.27

$

3.63

$

7.74

$

6.59

Less: comparability adjustments

Share-based compensation activity

0.14

0.10

0.23

0.11

Loss on equity investment

—

—

(0.05

)

—

Now-concluded litigation matter

—

—

—

0.08

Change from currency

0.06

—

0.20

—

$

4.07

$

3.53

$

7.36

$

6.40

Amounts presented may not recalculate due to rounding.

Projected 2026 comparable EPS growth outlined in the 2026 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) adjustment to projected full year 2026 reported EPS for estimated positive year-over-year foreign currency exchange rate change impact of $0.22 at noted exchange rates; (ii) adjustment to projected full year 2026 reported EPS for estimated positive impact of share-based compensation activity of $0.24; (iii) adjustment to projected full year 2026 EPS of $0.05 for unfavorable impact of a loss on an equity investment; (iv) adjustment to full year 2025 reported EPS for a positive $0.08 impact from the discrete litigation expense accrual adjustment in the second quarter of 2025; and (v) adjustment to full year 2025 reported EPS for positive impact of share-based compensation activity of $0.35.

These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2026 reported EPS growth) to comparable EPS growth for the Company.

Segment and Other Income from Operations - We report segment income from operations in our Segment Information table below. Segment income from operations is a non-GAAP financial measure that adjusts for the impact of foreign currency transaction gains and losses and should be considered in addition to, and not as a replacement for, or superior measure to, income from operations. We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations and report the full amount of foreign currency transaction gains and losses in Other. We believe that reporting segment income from operations provides supplemental analysis to help investors further evaluate each reportable segment’s business performance by excluding foreign currency transaction gains and losses, which are centrally managed by our corporate treasury function and which we do not consider relevant for assessing the results of each reportable segment’s operations. In addition, we believe that reporting segment income from operations provides information to investors regarding key metrics that are used by management, including our chief operating decision-maker, in evaluating the performance of each reportable segment.

The reconciliation of this non-GAAP financial measure is as follows for the three and six months ended June 30, 2026 and 2025:

Amounts in thousands | | Three Months Ended June 30,

| | 2026 | | 2025

| | Income from Operations | | Impact from Foreign Currency | | Segment and Other Income from Operations | | Income from Operations | | Impact from Foreign Currency | | Segment and Other Income from Operations

CAG | | $ | 393,069 | | | $ | 214 | | | $ | 393,283 | | | $ | 347,983 | | | $ | 494 | | | $ | 348,477 |

Water | | | 30,258 | | | | 16 | | | | 30,274 | | | | 24,606 | | | | 36 | | | | 24,642 |

LPD | | | 2,395 | | | | 16 | | | | 2,411 | | | | (543 | ) | | | 38 | | | | (505 | )

Other | | | (156 | ) | | | (246 | ) | | | (402 | ) | | | 1,000 | | | | (568 | ) | | | 432 |

Total | | $ | 425,566 | | | $ | — | | | $ | 425,566 | | | $ | 373,046 | | | $ | — | | | $ | 373,046 |

Amounts in thousands

CAG

$

393,069

$

214

$

393,283

$

347,983

$

494

$

348,477

Water

30,258

16

30,274

24,606

36

24,642

LPD

2,395

16

2,411

(543

)

38

(505

)

Other

(156

)

(246

)

(402

)

1,000

(568

)

432

$

425,566

$

—

$

425,566

$

373,046

$

—

$

373,046

Amounts in thousands | | Six Months Ended June 30,

| | 2026 | | 2025

| | Income from Operations | | Impact from Foreign Currency | | Segment and Other Income from Operations | | Income from Operations | | Impact from Foreign Currency | | Segment and Other Income from Operations

CAG | | $ | 730,234 | | $ | 604 | | | $ | 730,838 | | | $ | 642,554 | | | $ | 1,078 | | | $ | 643,632 |

Water | | | 53,901 | | | 42 | | | | 53,943 | | | | 45,380 | | | | 79 | | | | 45,459 |

LPD | | | 3,657 | | | 44 | | | | 3,701 | | | | (462 | ) | | | 82 | | | | (380 | )

Other | | | 360 | | | (690 | ) | | | (330 | ) | | | 2,108 | | | | (1,239 | ) | | | 869 |

Total | | $ | 788,152 | | $ | — | | | $ | 788,152 | | | $ | 689,580 | | | $ | — | | | $ | 689,580 |

Amounts in thousands

CAG

$

730,234

$

604

$

730,838

$

642,554

$

1,078

$

643,632

Water

53,901

42

53,943

45,380

79

45,459

LPD

3,657

44

3,701

(462

)

82

(380

)

Other

360

(690

)

(330

)

2,108

(1,239

)

869

$

788,152

$

—

$

788,152

$

689,580

$

—

$

689,580

Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company’s investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the three and six months ended June 30, 2026 and 2025. To estimate projected 2026 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $180 million. Free cash flow conversion, or the net income to free cash flow ratio, is a non-GAAP financial measure that is defined as free cash flow, with respect to a measurement period, divided by net income for the same period. To calculate trailing twelve-month net income to free cash flow ratio for the twelve months ended June 30, 2026, we have deducted purchases of property and equipment of approximately $117 million from net cash provided from operating activities of approximately $1,372 million, divided by net income of approximately $1,140 million.

Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges. Management believes that reporting Adjusted EBITDA, gross debt, and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

Discrete litigation expense accrual - During the first quarter of 2025, the Company reduced its previously established $89.0 million accrual related to a concluded litigation matter by approximately $9 million, which represented our best estimate at that time of the amount of the loss.

Concluded litigation matter - The Company was a defendant in a litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under an expired patent license agreement, and the trial court ruled in favor of the plaintiff in 2020. Following appeals and in light of the appellate court's April 3, 2025 decision, on April 17, 2025, the Company paid the judgment of approximately $80 million, and the plaintiff executed a satisfaction and release of judgment, which was filed with the trial court on the same date, concluding this matter. For further information, see the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

IDEXX Laboratories, Inc. and Subsidiaries | | | | | | |

Condensed Consolidated Statement of Operations | | | | | | |

Amounts in thousands except per share data (Unaudited) | | | | | | |

| | | | Three Months Ended | | Six Months Ended

| | | | June 30, | | June 30, | | June 30, | | June 30,

| | | | 2026 | | 2025 | | 2026 | | 2025

Revenue: | | Revenue | | $ | 1,216,585 | | | $ | 1,109,457 | | | $ | 2,357,405 | | | $ | 2,107,884 |

Expenses and Income: | | Cost of revenue | | | 437,498 | | | | 414,725 | | | | 855,579 | | | | 789,773 |

| | Gross profit | | | 779,087 | | | | 694,732 | | | | 1,501,826 | | | | 1,318,111 |

| | Sales and marketing | | | 171,277 | | | | 161,107 | | | | 346,527 | | | | 317,330 |

| | General and administrative | | | 116,815 | | | | 98,681 | | | | 235,930 | | | | 190,242 |

| | Research and development | | | 65,429 | | | | 61,898 | | | | 131,217 | | | | 120,959 |

| | Total operating expense | | | 353,521 | | | | 321,686 | | | | 713,674 | | | | 628,531 |

| | Income from operations | | | 425,566 | | | | 373,046 | | | | 788,152 | | | | 689,580 |

| | Non-operating income (expense), net | | | (8,342 | ) | | | (10,694 | ) | | | (15,486 | ) | | | (17,144 | )

| | Income before provision for income taxes | | | 417,224 | | | | 362,352 | | | | 772,666 | | | | 672,436 |

| | Provision for income taxes | | | 78,812 | | | | 68,363 | | | | 155,808 | | | | 135,770 |

Net Income: | | Net income attributable to stockholders | | $ | 338,412 | | | $ | 293,989 | | | $ | 616,858 | | | $ | 536,666 |

| | Earnings per share: Basic | | $ | 4.29 | | | $ | 3.66 | | | $ | 7.78 | | | $ | 6.64 |

| | Earnings per share: Diluted | | $ | 4.27 | | | $ | 3.63 | | | $ | 7.74 | | | $ | 6.59 |

| | Shares outstanding: Basic | | | 78,954 | | | | 80,413 | | | | 79,299 | | | | 80,864 |

| | Shares outstanding: Diluted | | | 79,312 | | | | 80,994 | | | | 79,742 | | | | 81,465 |

Amounts in thousands except per share data (Unaudited)

Revenue

$

1,216,585

$

1,109,457

$

2,357,405

$

2,107,884

Cost of revenue

437,498

414,725

855,579

789,773

Gross profit

779,087

694,732

1,501,826

1,318,111

Sales and marketing

171,277

161,107

346,527

317,330

General and administrative

116,815

98,681

235,930

190,242

Research and development

65,429

61,898

131,217

120,959

Total operating expense

353,521

321,686

713,674

628,531

Income from operations

425,566

373,046

788,152

689,580

Non-operating income (expense), net

(8,342

)

(10,694

)

(15,486

)

(17,144

)

Income before provision for income taxes

417,224

362,352

772,666

672,436

Provision for income taxes

78,812

68,363

155,808

135,770

Net income attributable to stockholders

$

338,412

$

293,989

$

616,858

$

536,666

Earnings per share: Basic

$

4.29

$

3.66

$

7.78

$

6.64

Earnings per share: Diluted

$

4.27

$

3.63

$

7.74

$

6.59

Shares outstanding: Basic

78,954

80,413

79,299

80,864

Shares outstanding: Diluted

79,312

80,994

79,742

81,465

IDEXX Laboratories, Inc. and Subsidiaries | | | | | | |

Selected Operating Information (Unaudited) | | | | | | |

| | | | Three Months Ended | | Six Months Ended

| | | | June 30, | | June 30, | | June 30, | | June 30,

| | | | 2026 | | 2025 | | 2026 | | 2025

Operating Ratios | | Gross profit | | 64.0 | % | | 62.6 | % | | 63.7 | % | | 62.5 | %

(as a percentage of revenue): | | Sales, marketing, general and administrative expense | | 23.7 | % | | 23.4 | % | | 24.7 | % | | 24.1 | %

| | Research and development expense | | 5.4 | % | | 5.6 | % | | 5.6 | % | | 5.7 | %

| | Income from operations1 | | 35.0 | % | | 33.6 | % | | 33.4 | % | | 32.7 | %

1Amounts presented may not recalculate due to rounding. | | | | | | |

Selected Operating Information (Unaudited)

Gross profit

64.0

%

62.6

%

63.7

%

62.5

%

(as a percentage of revenue):

Sales, marketing, general and administrative expense

23.7

%

23.4

%

24.7

%

24.1

%

Research and development expense

5.4

%

5.6

%

5.6

%

5.7

%

Income from operations1

35.0

%

33.6

%

33.4

%

32.7

%

1Amounts presented may not recalculate due to rounding.

IDEXX Laboratories, Inc. and Subsidiaries | | | |

Segment and Other Information | | | |

Amounts in thousands (Unaudited) | | | |

| | | | Three Months Ended

| | | | June 30, 2026 | | Percent of Revenue | | June 30, 2025 | | Percent of Revenue

Revenue: | | CAG | | $ | 1,118,236 | | | | | $ | 1,022,443 | | |

| | Water | | | 58,564 | | | | | | 51,001 | | |

| | LPD | | | 35,181 | | | | | | 31,762 | | |

| | Other | | | 4,604 | | | | | | 4,251 | | |

| | Total | | $ | 1,216,585 | | | | | $ | 1,109,457 | | |

Gross Profit: | | CAG | | $ | 715,787 | | | 64.0 | % | | $ | 642,102 | | | 62.8 | %

| | Water | | | 43,598 | | | 74.4 | % | | | 35,511 | | | 69.6 | %

| | LPD | | | 18,651 | | | 53.0 | % | | | 14,929 | | | 47.0 | %

| | Other | | | 1,051 | | | 22.8 | % | | | 2,190 | | | 51.5 | %

| | Total | | $ | 779,087 | | | 64.0 | % | | $ | 694,732 | | | 62.6 | %

Income from Operations: | | CAG | | $ | 393,283 | | | 35.2 | % | | $ | 348,477 | | | 34.1 | %

| | Water | | | 30,274 | | | 51.7 | % | | | 24,642 | | | 48.3 | %

| | LPD | | | 2,411 | | | 6.9 | % | | | (505 | ) | | (1.6 | %)

| | Other | | | (402 | ) | | (8.7 | %) | | | 432 | | | 10.2 | %

| | Total | | $ | 425,566 | | | 35.0 | % | | $ | 373,046 | | | 33.6 | %

Amounts in thousands (Unaudited)

CAG

$

1,118,236

$

1,022,443

Water

58,564

51,001

LPD

35,181

31,762

Other

4,604

4,251

Total

$

1,216,585

$

1,109,457

CAG

$

715,787

64.0

%

$

642,102

62.8

%

Water

43,598

74.4

%

35,511

69.6

%

LPD

18,651

53.0

%

14,929

47.0

%

Other

1,051

22.8

%

2,190

51.5

%

Total

$

779,087

64.0

%

$

694,732

62.6

%

CAG

$

393,283

35.2

%

$

348,477

34.1

%

Water

30,274

51.7

%

24,642

48.3

%

LPD

2,411

6.9

%

(505

)

(1.6

%)

Other

(402

)

(8.7

%)

432

10.2

%

Total

$

425,566

35.0

%

$

373,046

33.6

%

| | | | Six Months Ended

| | | | June 30, 2026 | | Percent of Revenue | | June 30, 2025 | | Percent of Revenue

Revenue: | | CAG | | $ | 2,172,288 | | | | | $ | 1,942,279 | | |

| | Water | | | 108,829 | | | | | | 96,322 | | |

| | LPD | | | 67,664 | | | | | | 60,358 | | |

| | Other | | | 8,624 | | | | | | 8,925 | | |

| | Total | | $ | 2,357,405 | | | | | $ | 2,107,884 | | |

Gross Profit: | | CAG | | $ | 1,383,296 | | | 63.7 | % | | $ | 1,216,925 | | | 62.7 | %

| | Water | | | 80,135 | | | 73.6 | % | | | 67,584 | | | 70.2 | %

| | LPD | | | 35,561 | | | 52.6 | % | | | 29,294 | | | 48.5 | %

| | Other | | | 2,834 | | | 32.9 | % | | | 4,308 | | | 48.3 | %

| | Total | | $ | 1,501,826 | | | 63.7 | % | | $ | 1,318,111 | | | 62.5 | %

Income from Operations: | | CAG | | $ | 730,838 | | | 33.6 | % | | $ | 643,632 | | | 33.1 | %

| | Water | | | 53,943 | | | 49.6 | % | | | 45,459 | | | 47.2 | %

| | LPD | | | 3,701 | | | 5.5 | % | | | (380 | ) | | (0.6 | %)

| | Other | | | (330 | ) | | (3.8 | %) | | | 869 | | | 9.7 | %

| | Total | | $ | 788,152 | | | 33.4 | % | | $ | 689,580 | | | 32.7 | %

CAG

$

2,172,288

$

1,942,279

Water

108,829

96,322

LPD

67,664

60,358

Other

8,624

8,925

Total

$

2,357,405

$

2,107,884

CAG

$

1,383,296

63.7

%

$

1,216,925

62.7

%

Water

80,135

73.6

%

67,584

70.2

%

LPD

35,561

52.6

%

29,294

48.5

%

Other

2,834

32.9

%

4,308

48.3

%

Total

$

1,501,826

63.7

%

$

1,318,111

62.5

%

CAG

$

730,838

33.6

%

$

643,632

33.1

%

Water

53,943

49.6

%

45,459

47.2

%

LPD

3,701

5.5

%

(380

)

(0.6

%)

Other

(330

)

(3.8

%)

869

9.7

%

Total

$

788,152

33.4

%

$

689,580

32.7

%

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)

| | Three Months Ended | | | | | | | | | |

| | June 30, 2026 | | June 30, 2025 | | Dollar Change | | Reported Revenue Growth1 | | Percentage Change from Currency | | Percentage Change from Acquisitions | | Organic Revenue Growth1

Net Revenue | | | | | | |

CAG | | $ | 1,118,236 | | $ | 1,022,443 | | $ | 95,793 | | 9.4 | % | | 0.6 | % | | — | | 8.7 | %

United States | | | 734,892 | | | 684,497 | | | 50,395 | | 7.4 | % | | — | | | — | | 7.4 | %

International | | | 383,344 | | | 337,946 | | | 45,398 | | 13.4 | % | | 1.9 | % | | — | | 11.5 | %

Water | | $ | 58,564 | | $ | 51,001 | | $ | 7,563 | | 14.8 | % | | 1.9 | % | | — | | 13.0 | %

United States | | | 29,621 | | | 26,090 | | | 3,531 | | 13.5 | % | | — | | | — | | 13.5 | %

International | | | 28,943 | | | 24,911 | | | 4,032 | | 16.2 | % | | 3.8 | % | | — | | 12.4 | %

LPD | | $ | 35,181 | | $ | 31,762 | | $ | 3,419 | | 10.8 | % | | 1.8 | % | | — | | 9.0 | %

United States | | | 6,608 | | | 5,767 | | | 841 | | 14.6 | % | | — | | | — | | 14.6 | %

International | | | 28,573 | | | 25,995 | | | 2,578 | | 9.9 | % | | 2.1 | % | | — | | 7.8 | %

Other | | $ | 4,604 | | $ | 4,251 | | $ | 353 | | 8.3 | % | | — | | | — | | 8.3 | %

Total Company | | $ | 1,216,585 | | $ | 1,109,457 | | $ | 107,128 | | 9.7 | % | | 0.7 | % | | — | | 9.0 | %

United States | | | 772,968 | | | 717,869 | | | 55,099 | | 7.7 | % | | — | | | — | | 7.7 | %

International | | | 443,617 | | | 391,588 | | | 52,029 | | 13.3 | % | | 2.0 | % | | — | | 11.2 | %

Amounts in thousands (Unaudited)

United States

734,892

684,497

50,395

7.4

%

—

—

7.4

%

International

383,344

337,946

45,398

13.4

%

1.9

%

—

11.5

%

United States

29,621

26,090

3,531

13.5

%

—

—

13.5

%

International

28,943

24,911

4,032

16.2

%

3.8

%

—

12.4

%

United States

6,608

5,767

841

14.6

%

—

—

14.6

%

International

28,573

25,995

2,578

9.9

%

2.1

%

—

7.8

%

United States

772,968

717,869

55,099

7.7

%

—

—

7.7

%

International

443,617

391,588

52,029

13.3

%

2.0

%

—

11.2

%

| | Three Months Ended | | | | | | | | | |

| | June 30, 2026 | | June 30, 2025 | | Dollar Change | | Reported Revenue Growth1 | | Percentage Change from Currency | | Percentage Change from Acquisitions | | Organic Revenue Growth1

Net CAG Revenue | | | | | | |

CAG Diagnostics recurring revenue: | | $ | 974,713 | | $ | 877,995 | | $ | 96,718 | | | 11.0 | % | | 0.7 | % | | — | | 10.3 | %

IDEXX VetLab consumables | | | 430,337 | | | 375,112 | | | 55,225 | | | 14.7 | % | | 1.1 | % | | — | | 13.6 | %

Rapid assay products | | | 101,575 | | | 100,240 | | | 1,335 | | | 1.3 | % | | 0.3 | % | | — | | 1.1 | %

Reference laboratory diagnostic and consulting services | | | 406,729 | | | 367,694 | | | 39,035 | | | 10.6 | % | | 0.3 | % | | — | | 10.3 | %

CAG Diagnostics services and accessories | | | 36,072 | | | 34,949 | | | 1,123 | | | 3.2 | % | | 1.1 | % | | — | | 2.1 | %

CAG Diagnostics capital – instruments | | $ | 47,174 | | $ | 58,600 | | ($ | 11,426 | ) | | (19.5 | %) | | 0.1 | % | | — | | (19.6 | %)

Veterinary software, services and diagnostic imaging systems: | | $ | 96,349 | | $ | 85,848 | | $ | 10,501 | | | 12.2 | % | | 0.4 | % | | — | | 11.8 | %

Recurring revenue | | | 76,343 | | | 68,954 | | | 7,389 | | | 10.7 | % | | 0.5 | % | | — | | 10.2 | %

Systems and hardware | | | 20,006 | | | 16,894 | | | 3,112 | | | 18.4 | % | | 0.2 | % | | — | | 18.2 | %

Net CAG revenue | | $ | 1,118,236 | | $ | 1,022,443 | | $ | 95,793 | | | 9.4 | % | | 0.6 | % | | — | | 8.7 | %

IDEXX VetLab consumables

430,337

375,112

55,225

14.7

%

1.1

%

—

13.6

%

Rapid assay products

101,575

100,240

1,335

1.3

%

0.3

%

—

1.1

%

Reference laboratory diagnostic and consulting services

406,729

367,694

39,035

10.6

%

0.3

%

—

10.3

%

CAG Diagnostics services and accessories

36,072

34,949

1,123

3.2

%

1.1

%

—

2.1

%

Recurring revenue

76,343

68,954

7,389

10.7

%

0.5

%

—

10.2

%

Systems and hardware

20,006

16,894

3,112

18.4

%

0.2

%

—

18.2

%

| | Three Months Ended | | | | | | | | | | |

| | June 30, 2026 | | June 30, 2025 | | Dollar Change | | Reported Revenue Growth1 | | Percentage Change from Currency | | Percentage Change from Acquisitions | | Organic Revenue Growth1 |

CAG Diagnostics recurring revenue: | | $ | 974,713 | | $ | 877,995 | | $ | 96,718 | | 11.0 | % | | 0.7 | % | | — | | 10.3 | % |

United States | | | 630,504 | | | 575,009 | | | 55,495 | | 9.7 | % | | — | | | — | | 9.7 | % |

International | | | 344,209 | | | 302,986 | | | 41,223 | | 13.6 | % | | 2.0 | % | | — | | 11.6 | % |

1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding. |

United States

630,504

575,009

55,495

9.7

%

—

—

9.7

%

International

344,209

302,986

41,223

13.6

%

2.0

%

—

11.6

%

1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)

| | Six Months Ended | | | | | | | | | |

| | June 30, 2026 | | June 30, 2025 | | Dollar Change | | Reported Revenue Growth1 | | Percentage Change from Currency | | Percentage Change from Acquisitions | | Organic Revenue Growth1

Net Revenue | | | | | | |

CAG | | $ | 2,172,288 | | $ | 1,942,279 | | $ | 230,009 | | | 11.8 | % | | 1.7 | % | | — | | 10.1 | %

United States | | | 1,425,792 | | | 1,308,386 | | | 117,406 | | | 9.0 | % | | — | | | — | | 9.0 | %

International | | | 746,496 | | | 633,893 | | | 112,603 | | | 17.8 | % | | 5.4 | % | | — | | 12.4 | %

Water | | $ | 108,829 | | $ | 96,322 | | $ | 12,507 | | | 13.0 | % | | 2.8 | % | | — | | 10.2 | %

United States | | | 56,014 | | | 49,593 | | | 6,421 | | | 12.9 | % | | — | | | — | | 12.9 | %

International | | | 52,815 | | | 46,729 | | | 6,086 | | | 13.0 | % | | 5.6 | % | | — | | 7.4 | %

LPD | | $ | 67,664 | | $ | 60,358 | | $ | 7,306 | | | 12.1 | % | | 4.0 | % | | — | | 8.2 | %

United States | | | 12,992 | | | 11,555 | | | 1,437 | | | 12.4 | % | | — | | | — | | 12.4 | %

International | | | 54,672 | | | 48,803 | | | 5,869 | | | 12.0 | % | | 4.8 | % | | — | | 7.2 | %

Other | | $ | 8,624 | | $ | 8,925 | | ($ | 301 | ) | | (3.4 | %) | | — | | | — | | (3.4 | %)

Total Company | | $ | 2,357,405 | | $ | 2,107,884 | | $ | 249,521 | | | 11.8 | % | | 1.8 | % | | — | | 10.0 | %

United States | | | 1,498,200 | | | 1,372,730 | | | 125,470 | | | 9.1 | % | | — | | | — | | 9.1 | %

International | | | 859,205 | | | 735,154 | | | 124,051 | | | 16.9 | % | | 5.3 | % | | — | | 11.6 | %

Amounts in thousands (Unaudited)

—

United States

1,425,792

1,308,386

117,406

9.0

%

—

—

9.0

%

International

746,496

633,893

112,603

17.8

%

5.4

%

—

12.4

%

United States

56,014

49,593

6,421

12.9

%

—

—

12.9

%

International

52,815

46,729

6,086

13.0

%

5.6

%

—

7.4

%

—

United States

12,992

11,555

1,437

12.4

%

—

—

12.4

%

International

54,672

48,803

5,869

12.0

%

4.8

%

—

7.2

%

—

United States

1,498,200

1,372,730

125,470

9.1

%

—

—

9.1

%

International

859,205

735,154

124,051

16.9

%

5.3

%

—

11.6

%

| | Six Months Ended | | | | | | | | | |

| | June 30, 2026 | | June 30, 2025 | | Dollar Change | | Reported Revenue Growth1 | | Percentage Change from Currency | | Percentage Change from Acquisitions | | Organic Revenue Growth1

Net CAG Revenue | | | | | | |

CAG Diagnostics recurring revenue: | | $ | 1,895,026 | | $ | 1,684,262 | | $ | 210,764 | | | 12.5 | % | | 1.8 | % | | — | | 10.7 | %

IDEXX VetLab consumables | | | 842,919 | | | 719,891 | | | 123,028 | | | 17.1 | % | | 2.6 | % | | — | | 14.5 | %

Rapid assay products | | | 186,513 | | | 184,274 | | | 2,239 | | | 1.2 | % | | 0.7 | % | | — | | 0.5 | %

Reference laboratory diagnostic and consulting services | | | 792,908 | | | 712,100 | | | 80,808 | | | 11.3 | % | | 1.4 | % | | — | | 10.0 | %

CAG Diagnostics services and accessories | | | 72,686 | | | 67,997 | | | 4,689 | | | 6.9 | % | | 2.3 | % | | — | | 4.6 | %

CAG Diagnostics capital – instruments | | $ | 89,623 | | $ | 90,594 | | ($ | 971 | ) | | (1.1 | %) | | 1.4 | % | | — | | (2.5 | %)

Veterinary software, services and diagnostic imaging systems: | | $ | 187,639 | | $ | 167,423 | | $ | 20,216 | | | 12.1 | % | | 0.7 | % | | — | | 11.4 | %

Recurring revenue | | | 149,879 | | | 134,747 | | | 15,132 | | | 11.2 | % | | 0.8 | % | | — | | 10.5 | %

Systems and hardware | | | 37,760 | | | 32,676 | | | 5,084 | | | 15.6 | % | | 0.3 | % | | — | | 15.2 | %

Net CAG revenue | | $ | 2,172,288 | | $ | 1,942,279 | | $ | 230,009 | | | 11.8 | % | | 1.7 | % | | — | | 10.1 | %

IDEXX VetLab consumables

842,919

719,891

123,028

17.1

%

2.6

%

—

14.5

%

Rapid assay products

186,513

184,274

2,239

1.2

%

0.7

%

—

0.5

%

Reference laboratory diagnostic and consulting services

792,908

712,100

80,808

11.3

%

1.4

%

—

10.0

%

CAG Diagnostics services and accessories

72,686

67,997

4,689

6.9

%

2.3

%

—

4.6

%

Recurring revenue

149,879

134,747

15,132

11.2

%

0.8

%

—

10.5

%

Systems and hardware

37,760

32,676

5,084

15.6

%

0.3

%

—

15.2

%

| | Six Months Ended | | | | | | | | | | |

| | June 30, 2026 | | June 30, 2025 | | Dollar Change | | Reported Revenue Growth1 | | Percentage Change from Currency | | Percentage Change from Acquisitions | | Organic Revenue Growth1 |

CAG Diagnostics recurring revenue: | | $ | 1,895,026 | | $ | 1,684,262 | | $ | 210,764 | | 12.5 | % | | 1.8 | % | | — | | 10.7 | % |

United States | | | 1,224,987 | | | 1,111,986 | | | 113,002 | | 10.2 | % | | — | | | — | | 10.2 | % |

International | | | 670,039 | | | 572,276 | | | 97,762 | | 17.1 | % | | 5.4 | % | | — | | 11.6 | % |

1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding. |

United States

1,224,987

1,111,986

113,002

10.2

%

—

—

10.2

%

International

670,039

572,276

97,762

17.1

%

5.4

%

—

11.6

%

1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Balance Sheet

Amounts in thousands (Unaudited)

| | | | June 30, 2026 | | December 31, 2025

Assets: | | Current Assets: | | | |

| | Cash and cash equivalents | | $ | 196,933 | | $ | 180,070

| | Accounts receivable, net | | | 627,083 | | | 552,378

| | Inventories | | | 391,579 | | | 377,756

| | Other current assets | | | 293,894 | | | 303,623

| | Total current assets | | | 1,509,489 | | | 1,413,827

| | Property and equipment, net | | | 733,238 | | | 747,380

| | Other long-term assets, net | | | 1,199,608 | | | 1,189,552

| | Total assets | | $ | 3,442,335 | | $ | 3,350,759

Liabilities and Stockholders' | | | | | |

Equity: | | Current Liabilities: | | | |

| | Accounts payable | | $ | 129,097 | | $ | 110,408

| | Accrued liabilities | | | 453,169 | | | 530,147

| | Line of credit | | | 519,000 | | | 398,000

| | Current portion of long-term debt | | | 149,999 | | | 74,995

| | Deferred revenue | | | 36,400 | | | 35,264

| | Total current liabilities | | | 1,287,665 | | | 1,148,814

| | Long-term debt, net of current portion | | | 299,865 | | | 374,842

| | Other long-term liabilities, net | | | 242,230 | | | 221,720

| | Total long-term liabilities | | | 542,095 | | | 596,562

| | Total stockholders' equity | | | 1,612,575 | | | 1,605,383

| | Total liabilities and stockholders' equity | | $ | 3,442,335 | | $ | 3,350,759

Amounts in thousands (Unaudited)

Cash and cash equivalents

$

196,933

$

180,070

Accounts receivable, net

627,083

552,378

Inventories

391,579

377,756

Other current assets

293,894

303,623

1,509,489

1,413,827

Property and equipment, net

733,238

747,380

Other long-term assets, net

1,199,608

1,189,552

$

3,442,335

$

3,350,759

Accounts payable

$

129,097

$

110,408

Accrued liabilities

453,169

530,147

Line of credit

519,000

398,000

Current portion of long-term debt

149,999

74,995

Deferred revenue

36,400

35,264

1,287,665

1,148,814

Long-term debt, net of current portion

299,865

374,842

Other long-term liabilities, net

242,230

221,720

542,095

596,562

1,612,575

1,605,383

$

3,442,335

$

3,350,759

IDEXX Laboratories, Inc. and Subsidiaries

Selected Balance Sheet Information (Unaudited)

| | | | June 30, 2026 | | March 31, 2026 | | December 31, 2025 | | September 30, 2025 | | June 30, 2025

Selected Balance Sheet Information: | | Days sales outstanding1 | | 46.2 | | 46.2 | | 46.8 | | 46.5 | | 44.7

| | Inventory turns2 | | 1.4 | | 1.4 | | 1.6 | | 1.5 | | 1.5

1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.

2Inventory turns are calculated as the ratio of our inventory-related cost of revenue for the quarter multiplied by four, divided by the average inventory balances at the beginning and end of each quarter.

Selected Balance Sheet Information (Unaudited)

Days sales outstanding1

46.2

46.2

46.8

46.5

44.7

Inventory turns2

1.4

1.4

1.6

1.5

1.5

1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.

2Inventory turns are calculated as the ratio of our inventory-related cost of revenue for the quarter multiplied by four, divided by the average inventory balances at the beginning and end of each quarter.

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Cash Flows

Amounts in thousands (Unaudited)

| | | | Six Months Ended

| | | | June 30, 2026 | | June 30, 2025

Operating: | | Cash Flows from Operating Activities: | | | |

| | Net income | | $ | 616,858 | | | $ | 536,666 |

| | Non-cash adjustments to net income | | | 143,240 | | | | 111,582 |

| | Changes in assets and liabilities | | | (146,688 | ) | | | (224,543 | )

| | Net cash provided by operating activities | | | 613,410 | | | | 423,705 |

Investing: | | Cash Flows from Investing Activities: | | | |

| | Purchases of property and equipment | | | (56,630 | ) | | | (64,128 | )

| | Acquisitions | | | (4,491 | ) | | | — |

| | Proceeds from net investment hedges | | | 2,081 | | | | 890 |

| | Net cash used by investing activities | | | (59,040 | ) | | | (63,238 | )

Financing: | | Cash Flows from Financing Activities: | | | |

| | Borrowings under credit facility, net | | | 121,000 | | | | 329,000 |

| | Payments of senior notes | | | — | | | | (103,386 | )

| | Repurchases of common stock | | | (697,840 | ) | | | (738,995 | )

| | Proceeds from exercises of stock options and employee stock purchase plans | | | 51,074 | | | | 24,523 |

| | Shares withheld for statutory tax withholding payments on restricted stock | | | (10,853 | ) | | | (7,094 | )

| | Net cash used by financing activities | | | (536,619 | ) | | | (495,952 | )

| | Net effect of changes in exchange rates on cash | | | (888 | ) | | | 11,813 |

| | Net increase (decrease) in cash and cash equivalents | | | 16,863 | | | | (123,672 | )

| | Cash and cash equivalents, beginning of period | | | 180,070 | | | | 288,266 |

| | Cash and cash equivalents, end of period | | $ | 196,933 | | | $ | 164,594 |

Amounts in thousands (Unaudited)

Net income

$

616,858

$

536,666

Non-cash adjustments to net income

143,240

111,582

Changes in assets and liabilities

(146,688

)

(224,543

)

Net cash provided by operating activities

613,410

423,705

Purchases of property and equipment

(56,630

)

(64,128

)

Acquisitions

(4,491

)

—

Proceeds from net investment hedges

2,081

890

Net cash used by investing activities

(59,040

)

(63,238

)

Borrowings under credit facility, net

121,000

329,000

Payments of senior notes

—

(103,386

)

Repurchases of common stock

(697,840

)

(738,995

)

Proceeds from exercises of stock options and employee stock purchase plans

51,074

24,523

Shares withheld for statutory tax withholding payments on restricted stock

(10,853

)

(7,094

)

Net cash used by financing activities

(536,619

)

(495,952

)

Net effect of changes in exchange rates on cash

(888

)

11,813

Net increase (decrease) in cash and cash equivalents

16,863

(123,672

)

Cash and cash equivalents, beginning of period

180,070

288,266

Cash and cash equivalents, end of period

$

196,933

$

164,594

IDEXX Laboratories, Inc. and Subsidiaries | | | |

Free Cash Flow | | | |

Amounts in thousands (Unaudited) | | | |

| | | | Three Months Ended | | Six Months Ended

| | | | June 30, 2026 | | June 30, 2025 | | June 30, 2026 | | June 30, 2025

Free Cash Flow: | | Net cash provided by operating activities | | $ | 347,162 | | | $ | 185,743 | | | $ | 613,410 | | | $ | 423,705 |

| | Investing cash flows attributable to purchases of property and equipment | | | (24,646 | ) | | | (34,102 | ) | | | (56,630 | ) | | | (64,128 | )

| | Free cash flow1 | | $ | 322,516 | | | $ | 151,641 | | | $ | 556,780 | | | $ | 359,577 |

1See Statement Regarding Non-GAAP Financial Measures, above. | | | |

Amounts in thousands (Unaudited)

Net cash provided by operating activities

$

347,162

$

185,743

$

613,410

$

423,705

Investing cash flows attributable to purchases of property and equipment

(24,646

)

(34,102

)

(56,630

)

(64,128

)

Free cash flow1

$

322,516

$

151,641

$

556,780

$

359,577

1See Statement Regarding Non-GAAP Financial Measures, above.

IDEXX Laboratories, Inc. and Subsidiaries | | | | | | |

Common Stock Repurchases | | | | | | |

Amounts in thousands except per share data (Unaudited) | | | | | | |

| | Three Months Ended | | Six Months Ended

| | June 30, 2026 | | June 30, 2025 | | June 30, 2026 | | June 30, 2025

Shares repurchased in the open market | | | 582 | | | 713 | | | 1,170 | | | 1,644

Shares acquired through employee surrender for statutory tax withholding | | | — | | | 2 | | | 17 | | | 16

Total shares repurchased | | | 582 | | | 715 | | | 1,187 | | | 1,660

Cost of shares repurchased in the open market | | $ | 332,046 | | $ | 327,530 | | $ | 692,879 | | $ | 736,745

Cost of shares for employee surrenders | | | 298 | | | 970 | | | 10,853 | | | 7,094

Total cost of shares | | $ | 332,344 | | $ | 328,500 | | $ | 703,732 | | $ | 743,839

Average cost per share – open market repurchases | | $ | 570.72 | | $ | 458.96 | | $ | 592.41 | | $ | 448.02

Average cost per share – employee surrenders | | $ | 563.62 | | $ | 513.46 | | $ | 627.34 | | $ | 452.84

Average cost per share – total | | $ | 570.71 | | $ | 459.10 | | $ | 592.92 | | $ | 448.07

Amounts in thousands except per share data (Unaudited)

Shares repurchased in the open market

582

713

1,170

1,644

Shares acquired through employee surrender for statutory tax withholding

—

2

17

16

Total shares repurchased

582

715

1,187

1,660

Cost of shares repurchased in the open market

$

332,046

$

327,530

$

692,879

$

736,745

Cost of shares for employee surrenders

298

970

10,853

7,094

Total cost of shares

$

332,344

$

328,500

$

703,732

$

743,839

Average cost per share – open market repurchases

$

570.72

$

458.96

$

592.41

$

448.02

Average cost per share – employee surrenders

$

563.62

$

513.46

$

627.34

$

452.84

Average cost per share – total

$

570.71

$

459.10

$

592.92

$

448.07

View source version on businesswire.com: https://www.businesswire.com/news/home/20260802055382/en/

John Ravis, Investor Relations investorrelations@idexx.com

Source: IDEXX Laboratories, Inc.

Released August 4, 2026